Ethnic Differences in Genetic Polymorphisms of CYP2D6, CYP2C19, CFPJ/ls and MDR1/ABCB1

Drug Metabolism And Pharmacokinetics

Volumn 19, Issue 2, 2004, Pages 83-95

  Ozawa, Shogo ^a   Soyama, Akiko ^a   Saeki, Mayumi ^a   Fukushima Uesaka, Hiromi ^a   Itoda, Masaya ^a   Koyano, Satoru ^a   Sai, Kimie ^a   Ohno, Yasuo ^a   Saito, Yoshiro ^a   Sawada, Jun Ichi ^a  

^a NATIONAL INSTITUTE OF HEALTH SCIENCES   (Japan)

Author keywords

ABC transporter; cytochrome P450; ethnic difference; genetic polymorphism; MDR1

Indexed keywords

ABC TRANSPORTER; ABC TRANSPORTER A1; CYP2C19 PROTEIN, HUMAN; CYTOCHROME P450 2D6; CYTOCHROME P450 3A; MIXED FUNCTION OXIDASE; N DEMETHYLASE; UNSPECIFIC MONOOXYGENASE;

ETHNIC GROUP; GENE; GENETIC POLYMORPHISM; GENETICS; HUMAN; OXIDATION REDUCTION REACTION; REVIEW;

ARYL HYDROCARBON HYDROXYLASES; ATP-BINDING CASSETTE TRANSPORTERS; CYTOCHROME P-450 CYP2D6; CYTOCHROME P-450 CYP3A; ETHNIC GROUPS; GENES, MDR; HUMANS; MIXED FUNCTION OXYGENASES; OXIDATION-REDUCTION; OXIDOREDUCTASES, N-DEMETHYLATING; POLYMORPHISM, GENETIC;

EID: 16544363963     PISSN: 13474367     EISSN: 18800920     Source Type: Journal    
DOI: 10.2133/dmpk.19.83     Document Type: Review

References (125)

1. Pirmohamed, M. and Park, B. K.: Cytochrome P450 enzyme polymorphisms and adverse drug reactions. Toxicology, 192: 23-32 (2003).
2. US-FDA: Guidance for Industry Collection of Race and Ethnicity Data in Clinical Trials (Draft Guidance), January, 2003. http://www.fda.gov/cder/guidance/5054dft.pdf
3. US-FDA: Draft Guidance for Industry: Pharmacogenomic Data Submissions, November, 2003. http://www.fda.gov/cder/guidance/5900dft.pdf
4. Mahgoub, A., Idle, J. R., Dring, L. G., Lancaster, R. and Smith, R. L.: Polymorphic hydroxylation of debrisoquin in man. Lancet, 2: 584-586 (1977).
5. Eichelbaum, M., Spannbrucker, N., Steincke, B. and Dengler, H. J.: Defective N-oxidation of sparteine in man: A new pharmacogenetic defect. Eur. J. Clin. Pharmacol., 16: 183-187 (1979).
6. Lou, Y. C., Ying, L., Bertilsson, L. and Sjoqvist, F.: Low frequency of slow debrisoquin hydroxylation in a native Chinese population. Lancet, 2: 852-853 (1987).
7. Sommers, D. K., Moncrieff, J. and Avenant, J.: Non-correlation between debrisoquine and metoprolol polymorphisms in the Venda. Hum. Toxicol., 8: 365-368 (1989).
8. Steiner, E., Bertilsson, L., Sawe, J., Bertling, I. and Sjoqvist, F.: Polymorphic debrisoquine hydroxylation in 757 Swedish subjects. Clin. Pharmacol. Ther., 44: 431-435 (1988).
9. Benitez, J., Llerena, A. and Cobaleda, J.: Debrisoquin oxidation polymorphism in a Spanish population. Clin. Pharmacol. Ther., 44: 74-77 (1988).
10. Kalow, W.: Pharmacogenetics in biological perspective. Pharmacol. Rev., 49: 369-379 (1997).
11. Linder, M. W., Prough, R. A. and Valdes Jr., R.: Pharmacogenetics: a laboratory tool for optimizing therapeutic efficiency. Clin. Chem., 43: 254-266 (1997).
12. Johansson, I., Yue, Q. Y., Dahl, M.-L., Heim, M., Sawe, J., Bertilsson, L., Meyer, U. A., Sjoqvist, F. and Ingelman-Sundberg, M.: Genetic analysis of the interethnic difference between Chinese and Caucasians in the polymorphic metabolism of debrisoquine and codeine. Eur. J. Clin. Pharmacol., 40: 553-556 (1991).
13. Hanioka, N., Kimura, S., Meyer, U. A. and Gonzalez, F. J.: The human CYP2D locus associated with a common genetic defect in drug oxidation: a G1934 to A base change in intron 3 of a mutant CYP2D6 allele results in an aberrant 3'-splice recognition site. Am. J. Hum. Genet., 47: 994-1001 (1990).
14. Yokota, H., Tamura, S., Furuya, H., Kimura, S., Watanabe, M., Kanazawa, I., Kondo, I. and Gonzalez, F. J.: Evidence for a new variant CYP2D6 allele CYP2D6J in a Japanese population associated with lower in vivo rates of sparteine metabolism. Pharmacogenetics, 3: 256-263 (1993).
15. Wang, S.-L., Huang, J.-D., Lai, M.-D., Liu, B.-H. and Lai, M.-L.: Molecular basis of genetic variation in debrisoquin hydroxylation in Chinese subjects: Polymorphism in RFLP and DNA sequence of CYP2D6. Clin. Pharmacol. Ther., 53: 410-418 (1993).
16. Tateishi, T., Chida, M., Ariyoshi, N., Mizorogi, Y., Kamataki, T. and Kobayashi, S.: Analysis of the CYP2D6 gene in relation to dextromethorphan O-demethylation capacity in a Japanese population. Clin. Pharmacol. Ther., 65: 570-575 (1999).
17. Shimada, T., Tsumura, F., Yamazaki, H., Guengerich, F. P. and Inoue, K.: Characterization of (á)-bufuralol hydroxylation activities in liver microsomes of Japanese and Caucasian subjects genotyped for CYP2D6. Pharmacogenetics, 11: 143-156 (2001).
18. Lin, K.-M., Poland, R. E., Lau, J. K. and Rubin, R. T.: Haloperidol and prolactin concentrations in Asians and Caucasians. J. Clin. Psychopharmacol., 8: 195-201 (1988).
19. Rudorfer, M. V., Lane, E. A., Chang, W.-H., Zhang, M. and Potter, W. Z.: Desipramine pharmacokinetics in Chinese and Caucasian volunteers. Br. J. Clin. Phamacol., 17: 433-440 (1984).
20. Yue, Q. Y., Svensson, J.-O., Alm, C., Sjoqvist, F. and Sawe, J.: Interindividual and interethnic differences in the demethylation and glucuronidation of codeine. Br. J. Clin. Phamacol., 28: 629-637 (1989).
21. Yue, Q. Y., Svensson, J.-O., Sjoqvist, F. and Sawe, J.: A comparison of the pharmacokinetics of codeine and its metabolites in healthy Chinese and Caucasian extensive hydroxylators of debrisoquine. Br. J. Clin. Phamacol., 31: 643-647 (1991).
22. Masubuchi, Y., Hosokawa, S., Horie, T., Suzuki, T., Ohmori, S., Kitada, M. and Narimatsu, S.: Cytochrome P450 isozymes involved in propranolol metabolism in human liver microsomes. The role of CYP2D6 as ring-hydroxylase and CYP1A2 as N-desisopropylase. Drug Metab. Dispos., 22: 909-915 (1994).
23. Yoshimoto, K., Echizen, H., Chiba, K., Tani, M. and Ishizaki, T.: Identification of human CYP isoforms involved in the metabolism of propranolol enantiomersáN-desisopropylation is mediated mainly by CYP1A2. Br. J. Clin. Phamacol., 39: 421-431 (1995).
24. Zhou, H.-H., Koshakji, R. P., Silberstein, D. J., Wilkinson, G. R. and Wood, A. J. J.: Racial difference in drug response. Altered sensitivity to and clearance of propranolol in men of Chinese descent as compared with American whites. New Engl. J. Med., 320: 565-570 (1989).
25. Johnson, J. A. and Burlew, B. S.: Racial differences in propranolol pharmacokinetics. Clin. Pharmacol. Ther., 51: 495-500 (1992).
26. Sowinski, K. M., Lima, J. J., Burlew, B. S., Massie, J. D. and Johnson, J. A.: Racial differences in propranolol enantiomer kinetics following simultaneous i.v. and oral administration. Br. J. Clin. Phamacol., 42: 339-346 (1996).
27. Sowinski, K. M., Burlew, B. S. and Johnson, J. A.: Racial differences in sensitivity to the negative chronotropic effects of propranolol in healthy men. Clin. Pharmacol. Ther., 57: 678-683 (1995).
28. Johnson, J. A. and Burlew, B. S.: Metoprolol metabolism via cytochrome P450IID6 in ethnic populations. Drug Metab. Dispos., 24: 350-355 (1996).
29. Johansson, I., Lundqvist, E., Bertilsson, L., Dahl, M., Sjoqvist, F. and Ingelman-Sundberg, M.: Inherited amplification of an active gene in the cytochrome P450 CYP2D locus as a cause of ultrarapid metabolism of debrisoquine. Proc. Natl. Acad. Sci. USA., 90: 11825-11829 (1993).
30. Masimirembwa, C., Persson, I., Bertilsson, L., Hasler, J. and Ingelman-Sundberg, M.: A novel mutant variant of the CYP2D6 gene (CYP2D6*17) common in a black African population: association with diminished debrisoquine hydroxylase activity. Br. J. Clin. Pharmacol., 42: 713-719 (1996).
31. Wennerholm, A., Johansson, I., Hidestrand, M., Bertilsson, L., Gustafsson, L. L. and Ingelman-Sundberg, M.: Characterization of the CYP2D6*29 allele commonly present in a black Tanzanian population causing reduced catalytic activity. Pharmacogenetics, 11: 417-427 (2001).
32. Gaedigk, A., Bradford, L. D., Marcucci, K. A. and Leeder, J. S.: Unique CYP2D6 activity distribution and genotype-phenotype discordance in black Americans. Clin. Pharmacol. Ther., 72: 76-89 (2002).
33. Gaedigk, A., Ndjountche, L., Gaedigk, R., Leeder, J. S. and Bradford, L. D.: Discovery of a novel nonfunctional cytochrome P450 2D6 allele, CYP2D6*42, in African American subjects. Clin. Pharmacol. Ther., 73: 575-576 (2003).
34. Gaedigk, A., Ryder, D. L., Bradford, L. D. and Leeder, J. S.: CYP2D6 poor metabolizer status can be ruled out by a single genotyping assay for the -1584G promoter polymorphism. Clin. Chem., 49: 1008-1011 (2003).
35. Zanger, U. M., Fischer, J., Raimundo, S., Stuven, T., Evert, B. O., Schwab, M. and Eichelbaum, M.: Comprehensive analysis of the genetic factors determining expression and function of hepatic CYP2D6. Pharmacogenetics, 11: 573-585 (2001).
36. Ji, L., Pan, S., Marti-Jaun, J., Hanseler, E., Rentsch, K. and Hersberger, M.: Single-step assays to analyze CYP2D6 gene polymorphisms in Asians: allele frequencies and a novel *14B allele in mainland Chinese. Clin. Chem., 48: 983-988 (2002).
37. Chida, M., Yokoi, T., Nemoto, N., Inaba, M., Kinoshita, M. and Kamataki, T.: A new variant CYP2D6 allele (CYP2D6*21) with a single base insertion in exon 5 in a Japanese population associated with a poor metabolizer phenotype. Pharmacogenetics, 9: 287-293 (1999).
38. Yamazaki, H., Kiyotani, K., Tsubuko, S., Matsunaga, M., Fujieda, M., Saito, T., Miura, J., Kobayashi, S. and Kamataki, T.: Two novel haplotypes of CYP2D6 gene in a Japanese population. Drug Metab. Pharmacokin., 18: 269-271 (2003).
39. Wrighton, S. A., Stevens, J. C., Becker, G. W. and VandenBranden, M.: Isolation and characterization of human liver cytochrome P450 2C19: Correlation between 2C19 and S-mephenytoin 4'-hydroxylation. Arch. Biochem. Biophys., 306: 240-245 (1993).
40. Goldstein, J. A., Faletto, M. B., Romkes-Sparks, M., Sullivan, T., Kitareewan, S., Raucy, J. L., Lasker, J. M. and Ghanayem, B. I.: Evidence that CYP2C19 is the major (S)-mephenytoin 4'-hydroxylase in human. Biochemistry, 33: 1743-1752 (1994).
41. Kupfer, A. and Preisig, R.: Pharmacogenetics of mephenytoin: A new drug hydroxylation polymorphism in man. Eur. J. Clin. Pharmacol., 26: 753-759 (1984).
42. Wedlund, P. J., Aslanian, W. S., McAllister, C. B., Wilkinson, G. R. and Branch, R. A.: Mephenytoin hydroxylation deficiency in Caucasians: Frequency of a new oxidative drug metabolism polymorphism. Clin. Pharmacol. Ther., 36: 773-780 (1984).
43. Nakamura, K., Goto, F., Ray, W. A., McAllister, C. B., Jacqz, E., Wilkinson, G. R. and Branch, R. A.: Interethnic differences in genetic polymorphism of debrisoquin and mephenytoin hydroxylation between Japanese and Caucasian populations. Clin. Pharmacol. Ther., 38: 402-408 (1985).
44. Ward, S. A., Goto, F., Nakamura, K., Jacqz, E., Wilkinson, G. R. and Branch, R. A.: S-mephenytoin 4-hydroxylase is inherited as an autosomal recessive trait in Japanese families. Clin. Pharmacol. Ther., 42: 96-99 (1987).
45. Masimirembwa, C., Bertilsson, L., Johansson, I., Hasler, J. A. and Ingelman-Sundberg, M.: Phenotyping and genotyping of S-mephenytoin hydroxylase (cytochrome P450 2C19) in a Shona population of Zimbabwe. Clin. Pharmacol. Ther., 57: 656-661 (1995).
46. de Morais, S. M. F., Wilkinson, G. R., Blaisdell, J., Nakamura, K., Meyer, U. A. and Goldstein, J. A.: The major genetic defect responsible for the polymorphism of S-mephennytoin metabolism in humans. J. Biol. Chem., 269: 15419-15422 (1994).
47. de Morais, S. M. F., Wilkinson, G. R., Blaisdell, J., Meyer, U. A., Nakamura, K. and Goldstein, J. A.: Identification of a new genetic defect responsible for the polymorphism of (S)-mephenytoin metabolism in Japanese. Mol. Pharmacol., 46: 594-598 (1994).
48. Takakubo, F., Kuwano, A. and Kondo, I.: Evidence that poor metabolizers of (S)-mephenytoin could be identified by haplotypes of CYP2C19 in Japanese. Pharmacogenetics, 6: 265-267 (1996).
49. Kubota, T., Chiba, K. and Ishizaki, T.: Genotyping of S-mephenytoin 4'-hydroxylation in an extended Japanese population. Clin. Pharmacol. Ther., 60: 661-666 (1996).
50. Tsuneoka, Y., Fukushima, K., Matsuo, Y., Ichikawa, Y. and Watanabe, Y.: Genotype analysis of the CYP2C19 gene in the Japanese population. Life Sci., 59: 1711-1715 (1996).
51. Kimura, M., Ieiri, I, Mamiya, K., Urae, A. and Higuchi, S.: Genetic polymorphism of cytochrome P450s, CYP2C19, and CYP2C9 in a Japanese population. Ther. Drug Monit., 20: 243-247 (1998).
52. Itoh, K., Inoue, K., Yanagiwara, S., Kyoya, H. and Suzuki, T.: A rapid and simple detection of genetic defects responsible for the phenotypic polymorphisms of cytochrome P450 2C19. Biol. Pharm. Bull., 22: 77-79 (1999).
53. Goldstein, J. A., Ishizaki, T., Chiba, K., de Morais, S. M. F., Bell, D., Krahn, P. M. and Evans, D. A. P.: Frequencies of the defective CYP2C19 alleles responsible for the mephenytoin poor metabolizer phenotype in various Oriental, Caucasian, Saudi Arabian and American black populations. Pharmacogenetics, 7: 59-64 (1997).
54. Ferguson, R. J., de Morais, S. M. F., Benhamou, S., Bouchardy, C., Blaisdell, J., Ibeanu, G., Wilkinson, G. R., Sarich, T. C., Wright, J. M., Dayer, P. and Goldstein, J. A.: A new genetic defect in human CYP2C19: mutation of the initiation codon is responsible for poor metabolism of S-mephenytoin. J. Pharmacol. Exp. Ther., 284: 356-361 (1998).
55. Xiao, Z.-S., Goldstein, J. A., Xie, H.-G., Blaisdell, J., Wang, W., Jiang, C.-H., Yan, F.-X., He, N., Huang, S.-L., Xu, Z.-H. and Zhou, H.-H.: Differences in the incidence of the CYP2C19 polymorphism affecting the S-mephenytoin phenotype in Chinese Han and Bai populations and identification of a new rare CYP2C19 mutant allele. J. Pharmacol. Exp. Ther., 281: 604-609 (1997).
56. Ibeanu, G. C., Blaisdell, J., Ghanayem, B. I., Beyeler, C., Benhamou, S., Bouchardy, C., Wilkinson, G. R., Dayer, P., Daly, A. K. and Goldstein, J. A.: An additional defective allele, CYP2C19*5, contributes to the S-mephenytoin poor metabolizer phenotype in Caucasians. Pharmacogenetics, 8: 129-135 (1998).
57. Ibeanu, G. C., Goldstein, J. A., Meyer, U. A., Benhamou, S., Bouchardy, C., Dayer, P., Burhan, I., Ghanayem, B. I. and Blaisdell, J.: Identification of new human CYP2C19 alleles (CYP2C19*6 and CYP2C19*2B) in a Caucasian poor metabolizer of mephenytoin. J. Pharmacol. Exp. Ther., 286: 1490-1495 (1998).
58. Ibeanu, G. C., Blaisdell, J., Ferguson, R. J., Ghanayem, B. I., Brosen, K., Benhamou, S., Bouchardy, C., Wilkinson, G. R., Dayer, P. and Goldstein, J. A.: A novel transversion in the intron 5 donor splice junction of CYP2C19 and a sequence polymorphism in exon 3 contribute to the poor metabolizer phenotype for the anticonvulsant drug S-mephenytoin. J. Pharmacol. Exp. Ther., 290: 635-640 (1999).
59. Blaisdell, J., Mohrenweiser, H., Jackson, J., Ferguson, S., Coulter, S., Channas, B., Xi, T., Ghanayem, B. I. and Goldstein, J. A.: Identification and functional characterization of new potentially defective alleles of human CYP2C19. Pharmacogenetics, 12: 703-711 (2002).
60. Zhang, Y., Reviriego, J., Lou, Y.-q., Sjoqvist, F. and Bertilsson, L.: Diazepam metabolism in native Chinese poor end extensive hydroxylators of S-mephenytoin: Interethnic differences in comparison with white subjects. Clin. Pharmacol. Ther., 48: 496-502 (1990).
61. Caraco, Y., Tateishi, T. and Wood, A. J. J.: Interethnic difference in omeprazole's inhibition of diazepam metabolism. Clin. Pharmacol. Ther., 58: 62-72 (1995).
62. Caraco, Y., Lagerstrom, P.-O. and Wood, A. J. J.: Ethnic and genetic determinants of omeprazole disposition and effect. Clin. Pharmacol. Ther., 60: 157-167 (1996).
63. Bertilsson, L., Henthorn, T. K., Sanz, E., Tybring, G., Sawe, J. and Villen, T.: Importance of genetic factors in the regulation of diazepam metabolism: relationship to S-mephenytoin, but not debrisoquin, hydroxylation phenotype. Clin. Pharmacol. Ther., 45: 348-355 (1989).
64. Caraco, Y., Wilkinson, G. R. and Wood, A. J. J.: Differences between white subjects and Chinese subjects in the in vivo inhibition of cytochrome P450s 2C19, 2D6 and 3A by omeprazole. Clin. Pharmacol. Ther., 60: 396-404 (1996).
65. Chiba, K., Kobayashi, K., Manabe, K., Tani, M., Kamataki, T. and Ishizaki, T.: Oxidative metabolism of omeprazole in human liver microsomes: co-segregation with S-mephenytoin 4-hydroxylation. J. Pharmacol. Exp. Ther., 226: 52-59 (1993).
66. Gellner, K., Eiselt, R., Hustert, E., Arnold, H., Koch, I., Haberl, M., Deglmann, C. J., Burk, O., Buntefuss, D., Escher, S., Bishop, C., Koebe, H.-G., Brinkmann, U., Klenk, H.-P., Kleine, K., Meyer, U. A. and Wojnowski, L.: Genomic organization of the human CYP3A locus: identification of a new, inducible CYP3A gene. Pharmacogenetics, 11: 111-121 (2001).
67. Lin, Y. S., Dowling, A. L., Quigey, S. D., Farin, F. M., Zhang, J., Lamba, J., Schuetz, E. G. and Thummel, K. E.: Co-regulation of CYP3A4 and CYP3A5 and contribution to hepatic and intestinal midazolam metabolism. Mol. Pharmacol., 62: 162-172 (2002).
68. Westlind-Johnsson, A., Malmebo, S., Johansson, A., Otter, C., Andersson, T. B., Johansson, I., Edwards, R. J., Boobis, A. R. and Ingelman-Sundberg, M.: Comparative analysis of CYP3A expression in human liver suggests only a minor role for CYP3A5 in drug metabolism. Drug Metab. Dispos., 31: 755-761 (2003).
69. DeWaziers, I., Cugnenc, P. H., Yang, C. S., Leroux, J.-P. and Beaune, P. H.: Cytochrome P450 isoenzymes, epoxide hydrolase and glutathione transferases in rat and human hepatic and extrahepatic tissues. J. Pharmacol. Exp. Ther., 253: 387-394 (1990).
70. Shimada, T., Yamazaki, H., Mimura, M., Inui, Y. and Guengerich, F. P.: Interindividual variations in human liver cytochrome P450 enzymes involved in the oxidation of drugs, carcinogens and toxic chemicals: Studies with liver microsomes of 30 Japanese and 30 Caucasians. J. Pharmacol. Exp. Ther., 270: 414-423 (1994).
71. Paine, M. F., Khalighi, M., Fisher, J. M., Shen, D. D., Kunze, K. L., Marsh, C. L., Perkins, J. D. and Thummel, K. E.: Characterization of inter-and intra-intestinal differences in human CYP3A-dependent metabolism. J. Pharmacol. Exp. Ther., 283: 1552-1562 (1997).
72. Aoyama, T., Yamano, S., Waxman, D. J., Lapenson, D. P., Meyer, U. A., Fischer, V., Tyndale, R., Inaba, T., Kalow, W., Gelboin, H. V. and Gonzalez, F. J.: Cytochrome P450 hPCN3, a novel cytochrome P-450IIIA gene product that is differentially expressed in adult human liver. J. Biol. Chem., 264: 10388-10395 (1989).
73. Wrighton, S. A., Brian, W. R., Sari, M. A., Iwasaki, M., Guengerich, F. P., Raucy, J. L., Molowa, D. T. and Vandenbranden, M.: Studies on the expression and metabolic capabilities of human liver cytochrome P450IIIA5 (HLp3). Mol. Pharmacol., 38: 207-213 (1990).
74. Tateishi, T., Watanabe, M., Moriya, H., Yamaguchi, S., Sato, T. and Kobayashi, S.: No ethnic difference between Caucasian and Japanese hepatic samples in the expression frequency of CYP3A5 and CYP3A7 proteins. Biochem. Pharmacol., 57: 935-939 (1999).
75. Domanski, T. L., Finta, C., Halpert, J. R. and Zaphiropoulos, P. G.: cDNA cloning and initial characterization of CYP3A43, a novel human cytochrome P450. Mol. Pharmacol., 59: 386-392 (2001).
76. Westlind, A., Malmebo, S. Johansson, I., Otter, C., Andersson, T. B., Ingelman-Sundberg, M. and Oscarson, M.: Cloning and tissue distribution of a novel human cytochrome P450 of the CYP3A subfamily, CYP3A43. Biochem. Biophys. Res. Commun., 281: 1349-1355 (2001).
77. Westlind, A., Lofberg, L., Tindberg, N., Andersson, T. B. and Ingelman-Sundberg, M.: Interindividual differences in hepatic expression of CYP3A4: relationship to genetic polymorphism in the 5'-upstream regulatory region. Biochem. Biophys. Res. Commun., 259: 201-205 (1999).
78. Lin, Y. S., Lockwood, G. F., Graham, M. A., Brian, W. R., Loi, C.-M., Dobrinska, M. R., Shen, D. D., Watkins, P. B., Wilkinson, G. R., Kharasch, E. D. and Thummel, K. E.: In-vivo phenotyping for CYP3A by a single-point determination of midazolam plasma concentration. Pharmacogenetics, 11: 781-791 (2001).
79. Lin, K.-M., Lau, J. K., Smith, R., Phillips, P., Antal, E. and Poland, R. E.: Comparison of alprazolam plasma levels in normal Asian and Caucasian male volunteers. Psychopharmacol., 96: 365-369 (1988).
80. Kinirons, M. T., Lang, C. C., He, H. B., Ghebreselasie, K., Shay, S., Robin, D. W. and Wood, A. J. J.: Triazolam pharmacokinetics and pharmacodynamics in Caucasians and Southern Asians: ethnicity and CYP3A activity. Br. J. Clin. Pharmacol., 41: 69-72 (1996).
81. Ahsan, C. H., Renwick, A. G., Macklin, B., Challenor, V. F., Waller, D. G. and George, C. F.: Ethnic differences in the pharmacokinetics of oral nifedipine. Br. J. Clin. Pharmacol., 31: 399-403 (1991).
82. Sowunmi, A., Rashid, T. J., Akinyinka, O. O. and Renwick, A. G.: Ethnic differences in nifedipine kinetics: comparisons between Nigerians, Caucasians and South Asians. Br. J. Clin. Pharmacol., 40: 489-493 (1995).
83. Ajir, K., Smith, M., Lin, K.-M., Fleishaker, J. C., Chambers, J. H., Anderson, D., Nuccio, I., Zheng, Y. and Poland, R. E.: The pharmacokinetics and pharmacodynamics of adinazolam: multi-ethnic comparisons. Psychopharmacol., 129: 265-270 (1997).
84. Yu, K.-S., Cho, J.-Y., Shon, J.-H., Bae, K.-S., Yi, S.-Y., Lim, H.-S., Jang, I.-J. and Shin, S.-G.: Ethnic differences and relationships in the oral pharmacokinetics of nifedipine and erythromycin. Clin. Pharmacol. Ther., 70: 228-236 (2001).
85. Tateishi, T., Watanabe, M., Nakura, H., Asoh, M., Shirai, H., Mizorogi, Y., Kobayashi, S., Thummel, K. E. and Wilkinson, G. R.: CYP3A activity in European American and Japanese men using midazolam as an in vivo probe. Clin. Pharmacol. Ther., 69: 333-339 (2001).
86. Murayama, N., Nakamura, T., Saeki, M., Soyama, A., Saito, Y., Sai, K., Ishida, S., Nakajima, O., Itoda, M., Ohno, Y., Ozawa, S. and Sawada, J.: CYP3A4 gene polymorphism influence testosterone 6β-hydroxylation. Drug Metab. Pharmacokin., 17: 150-156 (2002).
87. Nakamura, T., Saito, Y., Murayama, N., Saeki, M., Soyama, A., Sai, K., Ozawa, S. and Sawada, J. Apparent low frequency of sequence variability within the proximal promoter region of the cytochrome P450 (CYP) 3A5 gene in established cell lines from Japanese individuals. Biol. Pharm. Bull., 24: 954-957 (2001).
88. Saeki, M., Saito, Y., Nakamura, T., Murayama, N., Kim, S.-R., Ozawa, S., Komamura, K., Ueno, K., Kamakura, S., Nakajima, T., Saito, H., Kitamura, Y., Kamatani, N. and Sawada, J.: Single nucleotide polymorphisms and haplotype frequencies of CYP3A5 in a Japanese population. Hum Mutat., 21: 653 (Mutation in Brief #618) (2003).
89. Fukushima-Uesaka, H., Saito, Y., Watanabe, H., Shiseki, K., Saeki, M., Nakamura, T., Kurose, K., Sai, K., Komamura, K., Ueno, K., Kamakura, S., Kitakaze, M., Hanai, S., Nakajima, T., Matsumoto, K., Saito, H., Goto, Y.-i., Kimura, H., Katoh, M., Sugai, K., Minami, N., Shirao, K., Tamura, T., Yamamoto, N., Minami, H., Ohtsu, A., Yoshida, T., Saijo, N., Kitamura, Y., Kamatani, N., Ozawa, S. and Sawada, J.: Haplotypes of CYP3A4 and their close linkage with CYP3A5 haplotypes in a Japanese population. Hum. Mutat., 23: 100 (Mutation in Brief #681) (2004).
90. Kuehl, P., Zhang, J., Lin, Y., Lamba, J., Assem, M., Schuetz, J., Watkins, P. B., Daly, A., Wrighton, S. A., Hall, S. D., Maurel, P., Relling, M., Brimer, C., Yasuda, K., Venkataramanan, R., Strom, S., Thummel, K., Boguski, M. S. and Scheutz, E.: Sequence diversity in CYP3A promoters and characterization of the genetic basis of polymorphic CYP3A5 expression. Nat. Genet., 27: 383-391 (2001).
91. Lamba, J. K., Lin, Y. S., Schuetz, E. G. and Thummel, K. E.: Genetic contribution to variable human CYP3A-mediated metabolism. Adv. Drug Deliv. Rev., 54: 1271-1294 (2002).
92. Kocarek, T. A., Schuetz, E. G., Strom, S. C., Fisher, R. A. and Guzelian, P. S.: Comparative analysis of cytochrome P4503A induction in primary cultures of rat, rabbit, and human hepatocytes. Drug. Metab. Dispos., 23: 415-421 (1995).
93. Combalbert, J., Fabre, I., Fabre, G., Dalet, I., Derancourt, J., Cano, J. P. and Maurel P.: Metabolism of cyclosporin A. IV. Purification and identification of the rifampicin-inducible human liver cytochrome P-450 (cyclosporin A oxidase) as a product of P450IIIA gene subfamily. Drug. Metab. Dispos., 17: 197-207 (1989).
94. Watkins, P. B., Murray, S. A., Winkelman, L. G., Heuman, D. M., Wrighton, S. A. and Guzelian, P. S.: Erythromycin breath test as an assay of glucocorticoid-inducible liver cytochromes P-450. Studies in rats and patients. J. Clin. Invest., 83: 688-697 (1989).
95. Schuetz, E. G., Schuetz, J. D., Strom, S. C., Thompson, M. T., Fisher, R. A., Molowa, D. T., Li, D. and Guzelian P. S.: Regulation of human liver cytochromes P-450 in family 3A in primary and continuous culture of human hepatocytes. Hepatology, 18: 1254-1262 (1993).
96. Pitchard, L., Fabre, I., Fabre, G., Domergue, J., Saint Aubert, B., Mourad, G. and Maurel, P.: Cyclosporin A drug interactions. Screening for inducers and inhibitors of cytochrome P-450 (cyclosporin A oxidase) in primary cultures of human hepatocytes and in liver microsomes. Drug. Metab. Dispos., 18: 595-606 (1990).
97. Maurice, M., Pichard, L, Daujat, M., Fabre, I., Joyeux, H., Domergue, J. and Maurel, P.: Effects of imidazole derivatives on cytochromes P450 from human hepatocytes in primary culture. FASEB J., 6: 752-758 (1992).
98. Pichard, L, Fabre, I., Daujat, M., Domergue, J., Joyeux, H. and Maurel, P.: Effect of corticosteroids on the expression of cytochromes P450 and on cyclosporin A oxidase activity in primary cultures of human hepatocytes. Mol. Pharmacol., 41: 1047-1055 (1992).
99. Curi-Pedrosa, R., Daujat, M., Pichard, L., Ourlin, J. C., Clair, P., Gervot, L., Lesca, P., Domergue, J., Joyeux, H., and Fourtanier, G.: Omeprazole and lansoprazole are mixed inducers of CYP1A and CYP3A in human hepatocytes in primary culture. J. Pharmacol. Exp. Ther., 269: 384-392 (1994).
100. Kostrubsky, V. E., Lewis, L. D., Strom, S. C., Wood, S. G., Schuetz, E. G., Schuetz, J. D., Sinclair, P. R., Wrighton, S. A. and Sinclair, J. F.: Induction of cytochrome P4503A by taxol in primary cultures of human hepatocytes. Arch. Biochem. Biophys., 355: 131-136 (1998).
101. Sumida, A., Fukuen, S., Yamamoto, I., Matsuda, H., Naohara, M. and Azuma, J.: Quantitative analysis of constitutive and inducible CYPs mRNA expression in the HepG2 cell line using reverse transcription-competitive PCR. Biochem. Biophys. Res. Commun., 267: 756-760 (2000).
102. Synold, T. W., Dussault, I. and Forman, B. M.: The orphan nuclear receptor SXR coordinately regulates drug metabolism and efflux. Nat. Med., 7: 584-590 (2001).
103. Bertilsson, G., Heidrich, J., Svensson, K., Asman, M., Jendeberg, L., Sydow-Backman, M., Ohlsson, R., Postlind, H., Blomquist, P. and Berkenstam, A.: Identification of a human nuclear receptor defines a new signaling pathway for CYP3A induction. Proc. Natl. Acad. Sci., USA, 95: 12208-12213 (1998).
104. Blumberg, B., Sabbagh, W., Jr., Juguilon, H., Bolado, J., Jr., van Meter, C. M., Ong, E. S. and Evans, R. M.: SXR, a novel steroid and xenobiotic sensing nuclear receptor. Genes Dev., 12: 3195-3205 (1998).
105. Goodwin, B., Redinbo, M. R. and Kliewer, S. A.: Regulation of CYP3A gene transcription by the pregnane X receptor. Annu. Rev. Pharmacol. Toxicol., 42: 1-23 (2002).
106. Pascussi, J. M., Drocourt, L., Fabre, J. M., Maurel, P. and Vilarem, M. J.: Dexamethasone induces pregnane X receptor and retinoid X receptor-alpha expression in human hepatocytes: synergistic increase of CYP3A4 induction by pregnane X receptor activators. Mol. Pharmacol., 58: 361-372 (2000).
107. Goodwin, B., Hodgson, E. and Liddle, C.: The orphan human pregnane X receptor mediates the transcriptional activation of CYP3A4 by rifampicin through a distal enhancer module. Mol. Pharmacol., 56: 1329-1339 (1999).
108. Matsumura, K., Saito, T., Takahashi, Y., Ozeki, T., Kiyotani, K., Fujieda, M., Yamazaki, H., Kunitoh, H. and Kamataki, T.: Identification of a novel polymorphic enhancer of the human CYP3A4 gene. Mol. Pharmacol., 65: 326-334 (2004).
109. Hustert, E., Zibat, A., Presecan-Siedel, E., Eiselt, R., Mueller, R., Fuβ, C., Brehm, I., Brinkmann, U., Eichelbaum, M., Wojnowski, L. and Burk, O.: Natural protein variants of pregnane X receptor with altered transactivation activity toward CYP3A4. Drug Metab. Dispos.: 29: 1454-1459 (2001).
110. Zhang, J., Kuehl, P., Green, E. D., Touchman, J. W., Watkins, P. B., Daly, A., Hall, S. D., Maurel, P., Relling, M., Brimer, C., Yasuda, K., Wrighton, S. A., Hancock, M., Kim, R. B., Strom, S., Thummel, K., Russell, C. G., Hudson, J. R. Jr., Schuetz, E. G. and Boguski, M. S.: The human pregnane X receptor: genomic structure and identification and functional characterization of natural allelic variants. Pharmacogenetics, 11: 555-572 (2001).
111. Koyano, S., Kurose, K., Ozawa, S., Saeki, M., Nakajima, Y., Hasegawa, R., Komamura, K., Ueno, K., Kamakura, S., Nakajima, T., Saito, H., Kimura, H., Goto, Y.-i., Saitoh, O., Katoh, M., Ohnuma, T., Kawai, M., Sugai, K., Ohtsuki, T., Suzuki, C., Minami, N., Saito, Y. and Sawada, J.: Eleven novel single nucleotide polymorphisms in the NR1I2 (PXR) gene, four of which induce non-synonymous amino acid alterations. Drug Metab. Pharmacokin., 17: 561-565 (2003).
112. Koyano, S., Kurose, K., Saito, Y., Ozawa, S., Hasegawa, R., Komamura, K., Ueno, K., Kamakura, S., Kitakaze, M., Nakajima, T., Matsumoto, K., Akasawa, A., Saito, H. and Sawada, J.: Functional characterization of four naturally occurring variants of human pregnane X receptor (PXR): one variant causes dramatic loss of both DNA binding activity and the transactivation of the CYP3A4 promoter/enhancer region. Drug Metab. Dispos., 32: 149-154 (2004).
113. Fukuen, S., Fukuda, T., Matsuda, H., Sumida, A., Yamamoto, I., Inaba, T. and Azuma, J.: Identification of the novel splicing variants for the hPXR in human livers. Biochem. Biophys. Res. Commun., 298: 433-438 (2002).
114. Wolbold, R., Klein, K., Burk, O., Nussler, A. K., Neuhaus, P., Eichelbaum, M., Schwab, M. and Zanger, U. M.: Sex is a major determinant of CYP3A4 expression in human liver. Hepatology, 38: 978-988 (2003).
115. Schwab, M., Eichelbaum, M. and Fromm, M. F.: Genetic polymorphisms of the human MDR1 drug transporter. Annu. Rev. Pharmacol. Toxicol., 43: 285-307 (2003).
116. Hoffmeyer, S., Burk, O., von Richter, O., Arnold, H. P., Brockmoller, J., Johne, A., Cascorbi, I., Gerloff, T., Roots, I., Eichelbaum, M. and Brinkman, U.: Functional polymorphisms of the human multidrug-resistance gene: Multiple sequence variations and correlation of one allele with P-glycoprotein expression and activity in vivo. Proc. Natl. Acad. Sci. USA, 97: 3473-3478 (2000).
117. Sai, K., Kaniwa, N., Itoda, M., Saito, Y., Hasegawa, R., Komamura, K., Ueno, K., Kamakura, S., Kitakaze, M., Shirao, K., Minami, H., Ohtsu, A., Yoshida, T., Saijo, N., Kitamura, Y., Kamatani, N., Ozawa, S. and Sawada, J.: Haplotype analysis of ABCB1/MDR1 blocks in a Japanese population reveals genotype-dependent renal clearance of irinotecan. Pharmacogenetics, 13: 741-757 (2003).
118. Chu, X. Y., Suzuki, H., Ueda, K., Kato, Y., Akiyama, S. and Sugiyama, Y.: Active efflux of CPT-11 and its metabolites in human KB-derived cell lines. J. Pharmacol. Exp. Ther., 288: 735-741 (1999).
119. Yamamoto, W., Verweij, J., de Bruijn, P., de Jonge, M. J., Takano, H., Nishiyama, M., Kurihara, M. and Sparreboom, A.: Active transepithelial transport of irinotecan (CPT-11) and its metabolites by human intestinal Caco-2 cells. Anticancer Drugs, 12: 419-432 (2001).
120. Kim, R. B., Leake, B. F., Choo, E. F., Dresser, G. K., Kubba, S. V., Schwarz, U. I., Taylor, A., Xie, H.-G., McKinsey, J., Zhou, S., Lan, L.-B., Schuetz, J. D., Schuetz, E. G. and Wilkinson, G. R.: Identification of functionally variant MDR1 alleles among European Americans and African Americans. Clin. Pharmacol. Ther., 70: 189-199 (2001).
121. Kroetz, D. L., Pauli-Magnus, C., Hodges, L. M., Huang, C. C., Kawamoto, M., Johns, S. J., Stryke, D., Ferrin, T. E., DeYoung, J., Taylor, T., Carlson, E. J., Herskowitz, I., Giacomini, K. M. and Clark, A. G.: Sequence diversity and haplotype structure in the human ABCB1 (MDR1, multidrug resistance transporter) gene. Pharmacogenetics, 13: 481-494 (2003).
122. Marzolini, C., Paus, E., Buclin, T. and Kim, R. B.: Polymorphisms in human MDR1 (P-glycoprotein): Recent advances and clinical relevance. Clin. Pharmacol. Ther., 75: 13-33 (2004).
123. Goto, M., Masuda, S., Saito, H., Uemoto, S., Kiuchi, T., Tanaka, K. and Inui, K.-I.: C3435T polymorphism in the MDR1 gene affects the enterocyte expression level of CYP3A4 rather than Pgp in recipients of living-donor liver transplantation. Pharmacogenetics, 12: 451-457 (2002).
124. Johne, A., Kopke, K., Gerloff, T., Mai, I., Rietbrock, S., Meisel, C., Hoffmeyer, S., Kerb, R., Fromm, M. F., Brinkmann, U., Eichelbaum, M., Brockmoller, J., Cascorbi, I. and Roots, I.: Modulation of steady-state kinetics of digoxin by haplotypes of the P-glycoprotein MDR1 gene. Clin. Pharmacol. Ther., 72: 584-594 (2002).
125. Taniguchi, S., Mochida, Y., Uchiumi, T., Tahira, T., Hayashi, K., Takagi, K., Shimada, M., Maehara, Y., Kuwano, H., Kono, S., Nakano, H., Kuwano, M. and Wada, M.: Genetic polymorphism at the 5' regulatory region of multidrug resistance 1 (MDR1) and its association with interindividual variation of expression level in the colon. Mol. Cancer Ther., 2: 1351-1359 (2003).